JPMorgan Chase & Co. Lowers Organon & Co. (NYSE:OGN) Price Target to $12.00

Organon & Co. (NYSE:OGN) had its price target cut by stock analysts at JPMorgan Chase & Co. from $14.00 to $12.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 55.74% from the company’s previous close.

A number of other equities analysts have also weighed in on OGN. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Finally, Morgan Stanley lowered their price objective on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $12.50.

Organon & Co. Stock Up 2.5%

OGN stock opened at $7.71 on Tuesday. The stock’s 50 day simple moving average is $9.29 and its 200 day simple moving average is $9.47. The company has a market cap of $2.00 billion, a P/E ratio of 4.01, a price-to-earnings-growth ratio of 0.68 and a beta of 0.59. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.13 and a current ratio of 1.75. Organon & Co. has a fifty-two week low of $6.18 and a fifty-two week high of $17.23.

Hedge Funds Weigh In On Organon & Co.

Large investors have recently bought and sold shares of the stock. Hanson & Doremus Investment Management bought a new stake in shares of Organon & Co. in the 2nd quarter worth $26,000. Hantz Financial Services Inc. lifted its position in shares of Organon & Co. by 293.8% during the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after purchasing an additional 1,995 shares in the last quarter. Foster Dykema Cabot & Partners LLC purchased a new position in Organon & Co. during the third quarter worth about $29,000. Ransom Advisory Ltd purchased a new position in Organon & Co. during the first quarter worth about $32,000. Finally, SouthState Corp grew its position in Organon & Co. by 1,857.0% in the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock worth $38,000 after purchasing an additional 3,714 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.